This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| amyloid plaques | |
|---|---|
| Name | Amyloid plaques |
| Field | Neurology; Pathology |
| Symptoms | Cognitive decline; Memory loss; Neurodegeneration |
| Complications | Dementia; Neuroinflammation; Synaptic loss |
| Onset | Variable |
| Causes | Protein misfolding; Aggregation |
| Diagnosis | Histopathology; Neuroimaging |
| Treatment | Pharmacotherapy; Immunotherapy; Lifestyle interventions |
amyloid plaques are extracellular deposits of aggregated protein fibrils observed in the brains of patients with several neurodegenerative disorders. First described in neuropathological studies linked to Alzheimer's disease, they have been investigated across research institutions such as Harvard University, Massachusetts Institute of Technology, and Johns Hopkins University. Amyloid plaques are central to debates involving entities like the National Institutes of Health, Food and Drug Administration, and pharmaceutical firms including Biogen and Eli Lilly and Company.
Amyloid plaques were characterized historically in neuropathology by investigators at institutions including University of Cambridge, University College London, and the Karolinska Institute; contemporaneous work by researchers associated with Columbia University and University of California, San Francisco expanded molecular understanding. Clinical relevance spans dementia syndromes studied in clinics at Mayo Clinic and research consortia such as the Alzheimer's Disease Research Centers. Major awards recognizing contributions to protein aggregation include the Nobel Prize in Physiology or Medicine for related molecular discoveries, and foundational texts from publishers like Oxford University Press and Cambridge University Press summarize the field.
Plaques are composed primarily of misfolded peptide fragments derived from precursor proteins processed by enzymes whose discovery involved labs at Rockefeller University and Cold Spring Harbor Laboratory. The canonical peptide implicated in many plaques was identified through biochemical analyses performed at Scripps Research and structural studies at Max Planck Society facilities, with cryo-electron microscopy contributions from teams affiliated with ETH Zurich and The Rockefeller University. Enzymatic pathways implicating proteases were elucidated in collaborations with researchers at Stanford University and Yale University. Familial genetic mutations discovered in populations studied by groups at Imperial College London and Washington University in St. Louis highlighted variants that accelerate peptide aggregation.
Different amyloid types correspond to distinct precursor proteins described in disease-specific literature produced by centers such as Mount Sinai Hospital and University of Pennsylvania. The Aβ type associated with Alzheimer's disease has been contrasted with transthyretin-derived amyloid in studies from Mayo Clinic (Rochester) and hereditary forms characterized by clinicians at Oslo University Hospital. Cerebral amyloid angiopathy has been examined in cohorts from University of Toronto and KU Leuven, while prion protein deposits relevant to Creutzfeldt–Jakob disease were elucidated by investigators at University of Edinburgh and University of Tokyo.
Mechanistic models linking plaque deposition to synaptic dysfunction have been advanced by laboratories at Massachusetts General Hospital and computational groups at Princeton University and California Institute of Technology. Neuroinflammatory responses involving microglia and astrocytes have been characterized by researchers at University College London and Weill Cornell Medical College, with cytokine signaling pathways studied in collaborations including National Institute on Aging and Wellcome Trust-funded teams. Clinical-pathological correlations have been reported in cohort studies run by Alzheimer's Association consortia and longitudinal projects at Framingham Heart Study-affiliated groups.
Histopathological staining techniques were refined by pathologists from Mayo Clinic and Johns Hopkins Hospital, while immunohistochemistry protocols were standardized by laboratories at Rockefeller University and Harvard Medical School. In vivo imaging of plaque burden uses radioligands developed through partnerships involving Avid Radiopharmaceuticals, GE Healthcare, and academic centers including University of Pittsburgh Medical Center. Positron emission tomography studies linking amyloid signal to clinical outcomes have been conducted in multicenter trials coordinated by institutions such as University of California, Los Angeles and Vanderbilt University Medical Center.
Therapeutic approaches targeting plaques have been pursued by pharmaceutical companies including Roche, Pfizer, and Novartis in collaboration with academic medical centers like Mount Sinai Hospital. Immunotherapies and monoclonal antibodies were developed in industry-academic partnerships involving Genentech and Eli Lilly and Company, with regulatory interactions managed by the Food and Drug Administration and European Medicines Agency. Preventive strategies studied in randomized trials organized by groups at University of Oxford and Columbia University include lifestyle interventions evaluated in cohorts from Nord-Trøndelag Health Study and dietary research involving teams at Harvard T.H. Chan School of Public Health.
Ongoing basic research is driven by consortia such as the Human Genome Project-spinouts and initiatives funded by the National Institutes of Health and philanthropic organizations including the Bill & Melinda Gates Foundation for translational platforms. Recent clinical trials conducted at centers like Cleveland Clinic and Duke University Medical Center test small molecules, vaccines, and gene-based strategies developed in collaboration with biotechnology startups originating from Massachusetts Institute of Technology spinouts. Scientific dialogue continues at conferences hosted by societies including the Society for Neuroscience and the Alzheimer's Association International Conference, with peer-reviewed findings published in journals such as Nature, Science, and The Lancet.
Category:Neuropathology